Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of $(4.93) per share
Crescent Biopharma lost less money per share than experts thought it would, which is good news when a company is still in the losing phase. This shows the company is getting better at controlling costs, so watch if they keep improving or if losses start growing again.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.